Portfolio

HRT-001 is a compound raising HDL-C and that is to be administered orally daily in combinaison with an antioxidant at fixed dose. The molecule has been proven safe in large population of patients. The mechanism of action is triple via i)cholesterol efflux ii)reduction of oxidation and iii)decrease of hemoglobin polymerization. Through this combined MOA, this first in class therapy is aiming to be indicated for chronic treatment in patients suffering from Sickle Cell Disease (SCD). The treatment is anticipated to enter phase 2 in 2020.

HRT-002 is a ApoA-1 mimetic peptide formulated with sphingomyelin called Fx-5A and in-licensed from the National Institute of Health (NIH). The treatment consists as co-administration with an antioxidant at fixed dose. Fx-5A is an injectable first in class and its MOA is dual through i)cholesterol efflux and ii)reduction of oxidative stress. The therapy is aiming to be indicated for the treatment of vaso-occlusive crises in patients suffering from SCD. The treatment is anticipated to enter phase 1 by Q1/2020.

HRT-003 is a B-CAM Lutheran/Laminin inhibitor. Lutheran expression is increased in patients with sickle cells of SCD patients. The molecule is in preclinical stage.